Eurartesim: new combination malaria treatment

Eurartesim, a fixed-dose combination of piperaquine and dihydroartemisinin, is now available for the treatment of uncomplicated Plasmodium falciparum malaria in adults and children over 6 months.

The combination treatment includes piperaquine, which has good activity against chloroquine-resistant Plasmodium strains in vitro
The combination treatment includes piperaquine, which has good activity against chloroquine-resistant Plasmodium strains in vitro


Eurartesim is a combination of the bisquinolone, piperaquine, and dihydroartemisinin, the active metabolite of all artemisinin derivatives. The mechanism of action of piperaquine is unknown, but it is likely to act in a similar way to chloroquine, which prevents haem detoxification within the malaria parasite. Dihydroartemisinin has an endoperoxide bridge that is thought to be essential for its function, causing free-radical damage to parasite membranes.1


The efficacy of the piperaquine/dihydroartemisinin combination for the treatment of uncomplicated P. falciparum malaria was assessed in two randomised, open-label trials. The first study (n=1089) compared the combination with artesunate/mefloquine in adults and children in Asia,2 whereas the second study (n=1524) compared it with artemether/lumefantrine in children in Africa.3

Intention-to-treat analysis showed that 87.9% of patients treated with piperaquine/dihydroartemisinin were cured at day 63 in the Asian study, and 90.4% were cured at day 28 in the African study.

In both studies, the piperaquine/dihydroartemisinin combination was non-inferior to the comparator treatment, and had a similar safety profile.2,3 However, QT prolongation was observed more frequently and to a larger extent in patients receiving piperaquine/dihydroartemisinin than among those given the comparator treatments.1


  1. Eurartesim Summary of Product Characteristics, October 2011.
  2. Valecha N et al. PLoS ONE 2010; 5: e11880.
  3. Bassat Q et al. PLoS ONE 2009; 4: e7871.

View Eurartesim drug record
Further information: sigma-tau

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from MIMS

An elderly woman with one arm in a plaster cast sits resting both hands on her walker

Doctors urge NICE to reverse decision on new osteoporosis drug

More than NHS 100 clinicians have called on NICE to...

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Image of both strengths of Seffalair Spiromax inhaler side by side.

New salmeterol/fluticasone dry powder inhaler for asthma

Seffalair Spiromax is the sixth dry powder salmeterol/fluticasone...

An older man in a blue shirt and beige trousers leans forward on a sofa rubbing his painful lower back. Promoted

Established muscle relaxant offers new approach to managing back pain

Sponsored by Mibe Pharma

A muscle relaxant that has been used for decades outside the UK may provide an alternative to current treatments for low back pain, explains Dr Sunny Nayee, consultant in anaesthesia and pain medicine at Imperial College NHS Healthcare Trust.

Sponsored by Mibe Pharma UK Ltd. UK/MYO/21/044; December 2021.

Click here to view prescribing information for Myopridin® (pridinol mesilate)